Allianz Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,200
Closed -$81.7K – 2194
2026
Q2
$81.7K Buy
+10,200
New +$87.7K ﹤0.01% 2117
2025
Q4
– Sell
-26,000
Closed -$261K – 2089
2025
Q3
$261K Sell
26,000
-10,600
-29% -$152K ﹤0.01% 1928
2025
Q2
$639K Buy
+36,600
New +$528K ﹤0.01% 1770

Other funds holding SPRY

Allianz Asset Management's SPRY Position: Q3 2026 in Review

Allianz Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 10,200 shares — an estimated $81.7K sold.

Allianz Asset Management first reported a position in SPRY in Q2 2025 and held it in 3 quarters. The position peaked at $639K in Q2 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Allianz Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Allianz Asset Management sold 10,200 ARS Pharmaceuticals shares in Q3 2026, an estimated $81.7K.
  • Allianz Asset Management first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Allianz Asset Management's ARS Pharmaceuticals position peaked at $639K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Allianz Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.